Less than half of women with gestational diabetes get their recommended postpartum glucose screening, so tens of thousands silently progress to type 2 diabetes

When a woman is diagnosed with gestational diabetes during pregnancy, both the American College of Obstetricians and Gynecologists and the American Diabetes Association recommend a glucose tolerance test at 4 to 12 weeks postpartum. This screening is critical because 1 in 3 women with gestational diabetes already has impaired glucose metabolism at that postpartum test, and 40% to 70% will develop type 2 diabetes over their lifetime. Early detection allows lifestyle interventions or medication that can delay or prevent progression. The problem is that fewer than half of these women actually get screened. A 2024 study in Maternal-Fetal Medicine journal found a postpartum glucose screening completion rate of just 47.2%, and other studies report rates as low as 41%. With approximately 300,000 cases of gestational diabetes annually in the U.S., this means roughly 150,000 women per year leave the postpartum period without knowing whether they are prediabetic or already diabetic. Many of these women will not be screened again for years, until they show up with full-blown type 2 diabetes and its complications — retinopathy, neuropathy, kidney disease. The cost to the healthcare system is enormous, but the cost to the women is worse: they had a clear warning signal during pregnancy and a defined window for intervention, and the system let that window close. The structural failure has multiple layers. First, obstetric care ends at the 6-week postpartum visit, but the glucose test is supposed to happen during that same narrow window — and the 6-week visit itself has abysmal attendance rates. Second, there is a handoff gap: the OB who managed the gestational diabetes considers the pregnancy 'done,' and the primary care physician may not know the patient had GDM or may not prioritize the screening. Third, the postpartum period is chaotic for new mothers — sleep-deprived, caring for a newborn, possibly without childcare — and a fasting glucose tolerance test that takes 2+ hours at a lab is a logistically brutal ask. The Society for Maternal-Fetal Medicine has specifically flagged this as a quality gap, and quality improvement programs have shown they can push screening rates to 60-85%, but most health systems have not implemented them.